Abstract
Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have